+41 91 682 20 40 info@elixi-int.com

EMA recommends approval of the generic medicine Carmustine Obvius (carmustine), for the treatment brain tumours, non-Hodgkin’s lymphoma and Hodgkin’s disease.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the generic medicine Carmustine Obvius (carmustine), for the treatment of brain tumours, non-Hodgkin’s lymphoma and Hodgkin’s disease. Carmustine Obvius will be available…

Read More
  • 1
  • 2